期刊
JOURNAL OF IMMUNOLOGY
卷 194, 期 1, 页码 438-445出版社
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.1401344
关键词
-
类别
资金
- National Institutes of Health [R21CA167229, UL1RR024153, UL1TR000005, 1P50 CA097190]
- Roswell Park Cancer Institute/University of Pittsburgh Cancer Institute Ovarian Cancer Specialized Programs of Research Excellence [P50CA159981, R00HL097155]
- National Natural Science Foundation of China [31428005, 31320103918, 81273208, 81301389, 81273140]
- China Scholarship Council
- Shanghai Municipal Program of International Cooperation in Science and Technology [12410709800]
- Twelfth-Fifth Mega-Scientific Project on prevention and treatment of AIDS, viral hepatitis and other infectious diseases [2012ZX10003002]
- Shenzhen Science and Technology Innovation Project Grant [JCYJ20130329171031738]
Cancer immunotherapy has shown great promise as a new standard cancer therapeutic modality. However, the response rates are limited for current approach that depends on enhancing spontaneous antitumor immune responses. Therefore, increasing tumor immunogenicity by expressing appropriate cytokines should further improve the current immunotherapy. IL-33 is a member of the IL-1 family of cytokines and is released by necrotic epithelial cells or activated innate immune cells and is thus considered a danger signal. The role of IL-33 in promoting type 2 immune responses and tissue inflammation has been well established. However, whether IL-33 drives antitumor immune responses is controversial. Our previous work established that IL-33 promoted the function of CD8+ T cells. In this study, we showed that the expression of IL-33 in two types of cancer cells potently inhibited tumor growth and metastasis. Mechanistically, IL-33 increased numbers and IFN-gamma production by CD8+ T and NK cells in tumor tissues, thereby inducing a tumor microenvironment favoring tumor eradication. Importantly, IL-33 greatly increased tumor Ag-specific CD8+ T cells. Furthermore, both NK and CD8+ T cells were required for the antitumor effect of IL-33. Moreover, depletion of regulatory T cells worked synergistically with IL-33 expression for tumor elimination. Our studies established alarmin IL-33 as a promising new cytokine for tumor immunotherapy through promoting cancer-eradicating type 1 immune responses.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据